Advanced search
Publication Cover
Expert Review of Molecular Diagnostics Volume 14, 2014 - Issue 1
Submit an article Journal homepage
472
Views
33
CrossRef citations to date
0
Altmetric
Reviews

Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions

Maria Stella GrazianiAzienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy
&
Giampaolo MerliniDepartment of Molecular Medicine, University of Pavia, Foundation Scientific Institute San Matteo, Amyloidosis Research and Treatment Center, V.le Golgi 19, 27100, Pavia, ItalyCorrespondence[email protected]
Pages 55-66 | Published online: 28 Nov 2013

References

  • Bradwell AR, Carr-Smith HD, Mead GP et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin. Chem. 47(4), 673–680 (2001).
  • Keren DF. Procedures for the evaluation of monoclonal immunoglobulins. Arch. Pathol. Lab. Med. 123(2), 126–132 (1999).
  • Lavatelli F, Brambilla F, Valentini V et al. A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serum. Biochim. Biophys. Acta. 1814(3), 409–419 (2011).
  • Solomon A. Light chains of human immunoglobulins. Methods Enzymol. 116, 101–121 (1985).
  • Waldmann TA, Strober W, Mogielnicki RP. The renal handling of low molecular weight proteins. II. Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia. J. Clin. Invest. 51(8), 2162–2174 (1972).
  • Levinson SS, Keren DF. Free light chains of immunoglobulins: clinical laboratory analysis. Clin. Chem. 40(10), 1869–1878 (1994).
  • McLaughlin P, Alexanian R. Myeloma protein kinetics following chemotherapy. Blood 60(4), 851–855 (1982).
  • Katzmann JA, Clark RJ, Abraham RS et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains. Clin. Chem. 48(9), 1437–1444 (2002).
  • Hill PG, Forsyth JM, Rai B, Mayne S. Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies. Clin. Chem. 52(9), 1743–1748 (2006).
  • Hutchison CA, Harding S, Hewins P et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 3(6), 1684–1690 (2008).
  • Rao M, Yu WW, Chan J et al. Serum free light chain analysis for the diagnosis, management, and prognosis of plasma cell dyscrasias. In: AHRQ Comparative Effectiveness Reviews Number 73. Agency for Healthcare Research and Quality, Rockville, MD, USA (2012).
  • Charafeddine KM, Jabbour MN, Kadi RH, Daher RT. Extended use of serum free light chain as a biomarker in lymphoproliferative disorders: a comprehensive review. Am. J. Clin. Pathol. 137(6), 890–897 (2012).
  • Dispenzieri A, Kyle R, Merlini G et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23(2), 215–224 (2009).
  • Katzmann JA, Dispenzieri A, Kyle RA et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin. Proc. 81(12), 1575–1578 (2006).
  • Katzmann JA, Kyle RA, Benson J et al. Screening panels for detection of monoclonal gammopathies. Clin. Chem. 55(8), 1517–1522 (2009).
  • Abadie JM, Bankson DD. Assessment of serum free light chain assays for plasma cell disorder screening in a Veterans Affairs population. Ann. Clin. Lab. Sci. 36(2), 157–162 (2006).
  • Bakshi NA, Gulbranson R, Garstka D, Bradwell AR, Keren DF. Serum free light chain (FLC) measurement can aid capillary zone electrophoresis in detecting subtle FLC-producing M proteins. Am. J. Clin. Pathol. 124(2), 214–218 (2005).
  • Holding S, Spradbery D, Hoole R et al. Use of serum free light chain analysis and urine protein electrophoresis for detection of monoclonal gammopathies. Clin. Chem. Lab. Med. 49(1), 83–88 (2011).
  • Bird J, Behrens J, Westin J et al. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br. J. Haematol. 147(1), 22–42 (2009).
  • Bird J, Cavenagh J, Hawkins P, Lachmann H, Mehta A, Samson D. Guidelines on the diagnosis and management of AL amyloidosis. Br. J. Haematol. 125(6), 681–700 (2004).
  • Palladini G, Russo P, Bosoni T et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin. Chem. 55(3), 499–504 (2009).
  • Bochtler T, Hegenbart U, Heiss C et al. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. Haematologica 93(3), 459–462 (2008).
  • Merlini G, Palladini G. Differential diagnosis of monoclonal gammopathy of undetermined significance. Hematology Am. Soc. Hematol. Educ. Program 2012, 595–603 (2012).
  • Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 108(8), 2520–2530 (2006).
  • Kyle RA, Durie BG, Rajkumar SV et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24(6), 1121–1127 (2010).
  • Rajkumar SV, Kyle RA, Therneau TM et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106(3), 812–817 (2005).
  • Dispenzieri A, Kyle RA, Katzmann JA et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 111(2), 785–789 (2008).
  • Rajkumar SV, Merlini G, San Miguel JF. Haematological cancer: redefining myeloma. Nat. Rev. Clin. Oncol. 9(9), 494–496 (2012).
  • Mateos MV, Hernandez MT, Giraldo P et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N. Engl. J. Med. 369(5), 438–447 (2013).
  • Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 27(4), 941–946 (2013).
  • Kastritis E, Terpos E, Moulopoulos L et al. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia 27(4), 947–953 (2013).
  • Kyrtsonis MC, Vassilakopoulos TP, Kafasi N et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br. J. Haematol. 137(3), 240–243 (2007).
  • Snozek CL, Katzmann JA, Kyle RA et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia 22(10), 1933–1937 (2008).
  • van Rhee F, Bolejack V, Hollmig K et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 110(3), 827–832 (2007).
  • Munshi NC, Anderson KC, Bergsagel PL et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 117(18), 4696–4700 (2011).
  • Dispenzieri A, Lacy MQ, Katzmann JA et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 107(8), 3378–3383 (2006).
  • Kumar S, Dispenzieri A, Katzmann JA et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood 116(24), 5126–5129 (2010).
  • Kumar S, Dispenzieri A, Lacy MQ et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J. Clin. Oncol. 30(9), 989–995 (2012).
  • Dingli D, Kyle RA, Rajkumar SV et al. Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood 108(6), 1979–1983 (2006).
  • Berenson JR, Anderson KC, Audell RA et al. Monoclonal gammopathy of undetermined significance: a consensus statement. Br. J. Haematol. 150(1), 28–38 (2010).
  • Larson D, Kyle RA, Rajkumar SV. Prevalence and monitoring of oligosecretory myeloma. N. Engl. J. Med. 367(6), 580–581 (2012).
  • Durie BG, Harousseau JL, Miguel JS et al. International uniform response criteria for multiple myeloma. Leukemia 20(9), 1467–1473 (2006).
  • Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica 92(1), 143–144 (2007).
  • Kuhnemund A, Liebisch P, Bauchmuller K et al. ‘Light-chain escape-multiple myeloma’-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J. Cancer Res. Clin. Oncol. 135(3), 477–484 (2009).
  • Qu X, Zhang L, Fu W et al. An infrequent relapse of multiple myeloma predominantly manifesting as light chain escape: clinical experience from two Chinese centers. Leuk. Lymphoma 51(10), 1844–1849 (2010).
  • Lachmann HJ, Gallimore R, Gillmore JD et al. Correlation of changes in nephelometric quantification of serum monoclonal free light chains following chemotherapy and outcome in 137 patients with systemic AL amyloidosis. Clin. Chem. 48(6), E46 (2002).
  • Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood 121(26), 5124–5130 (2013).
  • Jaccard A, Bridoux F, Macro M et al. Risk adapted treatment strategy without autologous stem cell transplant (ASCT) in AL amyloidosis: the French experience since 2007. Clin. Lymphoma Myeloma Leuk. ( Suppl. 1), S258–S259 ( Abstract P-467) (2013).
  • Rajkumar SV, Harousseau JL, Durie B et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117(18), 4691–4695 (2011).
  • Dimopoulos M, Kyle R, Fermand JP et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 117(18), 4701–4705 (2011).
  • de Larrea CF, Cibeira MT, Elena M et al. Abnormal serum free light chain ratio in patients with multiple myeloma in complete remission has strong association with the presence of oligoclonal bands: implications for stringent complete remission definition. Blood 114(24), 4954–4956 (2009).
  • Singhal S, Vickrey E, Krishnamurthy J, Singh V, Allen S, Mehta J. The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios. Blood 114(1), 38–39 (2009).
  • Giarin MM, Giaccone L, Sorasio R et al. Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. Clin. Chem. 55(8), 1510–1516 (2009).
  • Paiva B, Martinez-Lopez J, Vidriales MB et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J. Clin. Oncol. 29(12), 1627–1633 (2011).
  • Iwama K, Chihara D, Tsuda K et al. Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma. Eur. J. Haematol. 90(2), 134–141 (2013).
  • Lachmann H, Gallimore R, Gillmore J et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br. J. Haematol. 122(1), 78–84 (2003).
  • Sanchorawala V, Seldin D, Magnani B, Skinner M, Wright D. Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant. 36(7), 597–600 (2005).
  • Palladini G, Lavatelli F, Russo P et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107(10), 3854–3858 (2006).
  • Palladini G, Barassi A, Klersy C et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 116(18), 3426–3430 (2010).
  • Pinney JH, Lachmann HJ, Bansi L et al. Outcome in renal Al amyloidosis after chemotherapy. J. Clin. Oncol. 29(6), 674–681 (2011).
  • Gertz MA, Comenzo R, Falk RH et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10(th) International Symposium on Amyloid and Amyloidosis. Am. J. Hematol. 79(4), 319–328 (2005).
  • Palladini G, Dispenzieri A, Gertz MA et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J. Clin. Oncol. 30(36), 4541–4549 (2012).
  • Abraham RS, Clark RJ, Bryant SC et al. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin. Chem. 48(4), 655–657 (2002).
  • Nowrousian MR, Brandhorst D, Sammet C et al. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin. Cancer Res. 11(24 Pt 1), 8706–8714 (2005).
  • Fulton RB, Fernando SL. Serum free light chain assay reduces the need for serum and urine immunofixation electrophoresis in the evaluation of monoclonal gammopathy. Ann. Clin. Biochem. 46(Pt 5), 407–412 (2009).
  • Beetham R, Wassell J, Wallage MJ, Whiteway AJ, James JA. Can serum free light chains replace urine electrophoresis in the detection of monoclonal gammopathies? Ann. Clin. Biochem. 44(Pt 6), 516–522 (2007).
  • Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet 361(9356), 489–491 (2003).
  • Dispenzieri A, Zhang L, Katzmann JA et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood 111(10), 4908–4915 (2008).
  • Singhal S, Stein R, Vickrey E, Mehta J. The serum-free light chain assay cannot replace 24-hour urine protein estimation in patients with plasma cell dyscrasias. Blood 109(8), 3611–3612 (2007).
  • Kaplan JS, Horowitz GL. Twenty-four-hour Bence-Jones protein determinations: can we ensure accuracy? Arch. Pathol. Lab. Med. 135(8), 1048–1051 (2011).
  • Gaspari F, Perico N, Remuzzi G. Timed urine collections are not needed to measure urine protein excretion in clinical practice. Am. J. Kidney Dis. 47(1), 1–7 (2006).
  • Graziani M, Merlini G, Petrini C. Guidelines for the analysis of Bence Jones protein. Clin. Chem. Lab. Med. 41(3), 338–346 (2003).
  • Tate J, Ferguson W, Callaghan L, Klingberg S, Marshall K, Koerbin G. The lack of harmonisation of methods for total urine protein (TUP) measurement. Clin. Biochem. Rev. 24, S18 (2003).
  • Jovanovich S, Tate J, Martin H, Wheatland L. Performance of urinary Bence Jones protein measurement in clinical laboratories. Clin. Biochem. Rev. 31, S30 (2010).
  • Beetham R. Detection of Bence-Jones protein in practice. Ann. Clin. Biochem. 37 (Pt 5), 563–570 (2000).
  • Boege F. Measuring Bence Jones proteins with antibodies against bound immunoglobulin light-chains: how reliable are the results? Eur. J. Clin. Chem. Clin. Biochem. 31(6), 403–405 (1993).
  • Levinson SS. Complementarily of urine analysis and serum free light chain assay for assessing response treatment response: illustrated by three case examples. Clin. Chim. Acta 412(23–24), 2206–2210 (2011).
  • Levinson SS. Urine immunofixation electrophoresis remains important and is complementary to serum free light chain. Clin. Chem. Lab. Med. 49(11), 1801–1804 (2011).
  • Shaheen SP, Levinson SS. Serum free light chain analysis may miss monoclonal light chains that urine immunofixation electrophoreses would detect. Clin. Chim. Acta 406(1–2), 162–166 (2009).
  • Merlini G. Serum-free light chain analysis: works in progress. Clin. Chem. Lab. Med. 47(9), 1021–1022 (2009).
  • Tate J, Bazeley S, Sykes S, Mollee P. Quantitative serum free light chain assay - analytical issues. Clin. Biochem. Rev. 30(3), 131–140 (2009).
  • Tate JR, Mollee P, Dimeski G, Carter AC, Gill D. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clin. Chim. Acta 376(1–2), 30–36 (2007).
  • Altinier S, Seguso M, Zaninotto M et al. Serum free light chain reference values: a critical approach. Clin. Biochem. 46(7–8), 691–693 (2013).
  • Briand PY, Decaux O, Caillon H, Grosbois B, Le Treut A, Guenet L. Analytical performance of the serum free light chain assay. Clin. Chem. Lab. Med. 48(1), 73–79 (2010).
  • Vercammen M, Meirlaen P, Broodtaerts L, Vande Broek I, Bossuyt X. Effect of sample dilution on serum free light chain concentration by immunonephelometric assay. Clin. Chim. Acta 412(19–20), 1798–1804 (2011).
  • Abraham RS, Charlesworth MC, Owen BA et al. Trimolecular complexes of lambda light chain dimers in serum of a patient with multiple myeloma. Clin. Chem. 48(10), 1805–1811 (2002).
  • Emond J-P, Harding S, Lemieux B. Aggregation of serum free light chains (FLC) causes overestimation of FLC nephelometric results as compared to serum protein electrophoresis (SPE) while preserving clinical usefulness. ASH Annual Meeting Abstracts 110(11), 4767 (2007).
  • de Kat Angelino CM, Raymakers R, Teunesen MA, Jacobs JF, Klasen IS. Overestimation of serum kappa free light chain concentration by immunonephelometry. Clin. Chem. 56(7), 1188–1190 (2010).
  • Daval S, Tridon A, Mazeron N, Ristori JM, Evrard B. Risk of antigen excess in serum free light chain measurements. Clin. Chem. 53(11), 1985–1986 (2007).
  • Murata K, Clark RJ, Lockington KS, Tostrud LJ, Greipp PR, Katzmann JA. Sharply increased serum free light-chain concentrations after treatment for multiple myeloma. Clin. Chem. 56(1), 16–18 (2010).
  • Levinson SS. Regarding the overestimation of serum kappa free light chains. Clin. Chem. 57(5), 775–777 (2011).
  • Jenner E, Levoguer A, Evans J, Harding S. Serum free light chain immunoassays: a guide to antigen excess detection. Clin. Chim. Acta 413(9–10), 949; author reply 952 (2012).
  • Pattenden RJ, Rogers SY, Wenham PR. Serum free light chains; the need to establish local reference intervals. Ann. Clin. Biochem. 44(Pt 6), 512–515 (2007).
  • Wang L, Chan PC. Measurement uncertainty for serum free light chain assays: estimation and implication on result interpretation. Clin. Biochem. 46(4–5), 381–384 (2013).
  • te Velthuis H, Knop I, Stam P et al. N Latex FLC - new monoclonal high-performance assays for the determination of free light chain kappa and lambda. Clin. Chem. Lab. Med. 49(8), 1323–1332 (2011).
  • Pretorius CJ, Klingberg S, Tate J, Wilgen U, Ungerer JP. Evaluation of the N Latex FLC free light chain assay on the Siemens BN analyser: precision, agreement, linearity and variation between reagent lots. Ann. Clin. Biochem. 49(Pt 5), 450–455 (2012).
  • Hoedemakers RM, Pruijt JF, Hol S et al. Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis. Clin. Chem. Lab. Med. 50(3), 489–495 (2012).
  • Schneider N, Wynckel A, Kolb B, Sablon E, Gillery P, Maquart FX. Comparative analysis of immunoglobulin free light chains quantification by Freelite (The Binding Site) and N Latex FLC (Siemens) methods. Ann. Biol. Clin. (Paris) 71(1), 13–19 (2013).
  • Lock R, Saleem R, Roberts E et al. A multicentre study comparing two methods for serum free light chain analysis. Ann. Clin. Biochem. 50(Pt 3), 255–261 (2013).
  • Berlanga O, Popat R, Oakervee H et al. Analytical comparison of polyclonal versus monoclonal antibody based free light chain (FLC) assays in multiple myeloma patients. Biochim. Clin. 37(SS), 1 (2013).
  • Rebolido M, Perez Suarez L, Barbosa Carvalho N. Comparison of two different immunoassays for the detection of immunoglobulin’s serum free light chains. Biochim. Clin. 37(SS), 616 (2013).
  • Wassef N. Comparison of the analytical performance of the polyclonal antibody based freelite and monoclonal antibody based N latex FLC assays in the detection of multiple myeloma and AL amyloidosis. Biochim. Clin. 37(SS), 642 (2013).
  • Palladini G, Bosoni T, Milani P et al. Use of the novel monoclonal assay for the measurement of circulating free light chain in the diagnosis, prognostication of survival and assessment of response to therapy in AL amyloidosis. ASH Annual Meeting Abstracts 120(21), 3913 (2012).
  • Mollee P, Tate J, Pretorius CJ. Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosis. Clin. Chem. Lab. Med. 1–8 (2013).
  • Campbell JP, Cobbold M, Wang Y et al. Development of a highly-sensitive multi-plex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine. J. Immunol. Methods 391(1–2), 1–13 (2013).
  • Linnet K, Bossuyt PM, Moons KG, Reitsma JB. Quantifying the accuracy of a diagnostic test or marker. Clin. Chem. 58(9), 1292–1301 (2012).
  • Vermeersch P, Van Hoovels L, Delforge M, Marien G, Bossuyt X. Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal B-cell disorder. Br. J. Haematol. 143(4), 496–502 (2008).
  • Jenner E. Serum free light chains in clinical laboratory diagnostics. Clin. Chim. Acta 427C, 15–20 (2013).
  • Price CP. Evidence-based laboratory medicine: supporting decision-making. Clin. Chem. 46(8 Pt 1), 1041–1050 (2000).
  • Waldenstrom J. Sick molecules and our concepts of disease. J. Intern. Med. 225(4), 221–227 (1989).
  • Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. J. Clin. Oncol. 29(14), 1924–1933 (2011).
  • Comenzo RL, Reece D, Palladini G et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 26(11), 2317–2325 (2012).
  • Dispenzieri A, Stewart AK, Chanan-Khan A et al. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood doi:10.1182/blood-2013-08-520890 (2013) ( Epub ahead of print).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.